Lucas Research (Diabetes & Endocrinology Consultants, PC)
Welcome,         Profile    Billing    Logout  
 8 Trials 
28 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lucas, Kathryn Jean
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Active, not recruiting
4
780
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Antihyperglycemic medication
Eli Lilly and Company
Type 2 Diabetes
10/25
11/27
DREAM-T2D, NCT04854512 / 2020-000763-23: Investigational Study of Delayed Release Metformin

Suspended
3
675
Europe, Canada, US, RoW
Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo
Anji Pharma
Diabetes Mellitus, Type 2
12/23
06/24
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
CATT1, NCT06334133: Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

Recruiting
3
150
US
Cadisegliatin 800 mg QD, TTP399, Cadisegliatin 800 mg BID, Placebo
vTv Therapeutics
Diabetes Mellitus, Type 1
09/26
10/26
ADVANCE, NCT06672549: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Recruiting
3
125
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight
02/27
03/27
NCT06672939: A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Recruiting
3
125
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight
02/27
03/27
NCT05758415: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Terminated
3
60
Europe, US, RoW
Secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Rotator Cuff Tendinopathy
10/24
12/24
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
SURPASS-T1D-1, NCT06914895: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Recruiting
3
905
Europe, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Type 1 Diabetes, Obesity, Overweight
05/27
05/27
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2/3
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
03/25
09/25
ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated
2b
98
Europe, Canada, US, RoW
EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo
Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.
Non-Alcoholic Steatohepatitis
10/21
11/21
NCT05591079: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

Completed
2
99
US
CS0159 (Linafexor), placebo
Cascade Pharmaceuticals, Inc, Laboratory Corporation of America
Nonalcoholic Steatohepatitis (NASH)
11/23
11/23
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1217
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
09/26
11/26
ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting
2
186
Canada, US
Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg
Zucara Therapeutics Inc.
Type 1 Diabetes Mellitus with Hypoglycemia
06/25
07/25
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06598631: Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease

Terminated
2
8
Europe, Japan, US, RoW
Volenrelaxin, LY3540378, Placebo
Eli Lilly and Company
Chronic Kidney Disease
12/24
12/24
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
275
US
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
NCT06074562: A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Completed
2
405
Europe, Japan, US, RoW
LY3556050, Placebo
Eli Lilly and Company
Diabetic Peripheral Neuropathy
06/25
06/25
NCT06897475: A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Recruiting
2
240
Europe, Canada, US
LY3457263, Placebo
Eli Lilly and Company
Type 2 Diabetes
12/26
01/27
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects

Active, not recruiting
2
215
US, RoW
HM15211, efocipegtrutide, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
06/26
07/26
SKYLINE, NCT06104319: Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH

Active, not recruiting
2
61
US
GSK4532990
GlaxoSmithKline
Non-alcoholic Fatty Liver Disease
09/25
09/25
NCT07030868: A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

Not yet recruiting
2
150
US, RoW
LY6249492, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
09/26
11/26
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
284
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
01/26
04/27
NCT05864391: A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

Terminated
1
40
US
AZD7503
AstraZeneca
Steatohepatitis
03/24
03/24
Gann, Crystal
NCT04783181: A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)

Active, not recruiting
1/2
8
US
AAV BBP-631
Adrenas Therapeutics Inc
Congenital Adrenal Hyperplasia
02/29
02/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lucas, Kathryn Jean
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Active, not recruiting
4
780
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Antihyperglycemic medication
Eli Lilly and Company
Type 2 Diabetes
10/25
11/27
DREAM-T2D, NCT04854512 / 2020-000763-23: Investigational Study of Delayed Release Metformin

Suspended
3
675
Europe, Canada, US, RoW
Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo
Anji Pharma
Diabetes Mellitus, Type 2
12/23
06/24
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
CATT1, NCT06334133: Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

Recruiting
3
150
US
Cadisegliatin 800 mg QD, TTP399, Cadisegliatin 800 mg BID, Placebo
vTv Therapeutics
Diabetes Mellitus, Type 1
09/26
10/26
ADVANCE, NCT06672549: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Recruiting
3
125
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight
02/27
03/27
NCT06672939: A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Recruiting
3
125
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight
02/27
03/27
NCT05758415: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Terminated
3
60
Europe, US, RoW
Secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Rotator Cuff Tendinopathy
10/24
12/24
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
SURPASS-T1D-1, NCT06914895: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Recruiting
3
905
Europe, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Type 1 Diabetes, Obesity, Overweight
05/27
05/27
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2/3
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
03/25
09/25
ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated
2b
98
Europe, Canada, US, RoW
EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo
Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.
Non-Alcoholic Steatohepatitis
10/21
11/21
NCT05591079: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

Completed
2
99
US
CS0159 (Linafexor), placebo
Cascade Pharmaceuticals, Inc, Laboratory Corporation of America
Nonalcoholic Steatohepatitis (NASH)
11/23
11/23
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1217
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
09/26
11/26
ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting
2
186
Canada, US
Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg
Zucara Therapeutics Inc.
Type 1 Diabetes Mellitus with Hypoglycemia
06/25
07/25
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06598631: Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease

Terminated
2
8
Europe, Japan, US, RoW
Volenrelaxin, LY3540378, Placebo
Eli Lilly and Company
Chronic Kidney Disease
12/24
12/24
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
275
US
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
NCT06074562: A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Completed
2
405
Europe, Japan, US, RoW
LY3556050, Placebo
Eli Lilly and Company
Diabetic Peripheral Neuropathy
06/25
06/25
NCT06897475: A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Recruiting
2
240
Europe, Canada, US
LY3457263, Placebo
Eli Lilly and Company
Type 2 Diabetes
12/26
01/27
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects

Active, not recruiting
2
215
US, RoW
HM15211, efocipegtrutide, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
06/26
07/26
SKYLINE, NCT06104319: Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH

Active, not recruiting
2
61
US
GSK4532990
GlaxoSmithKline
Non-alcoholic Fatty Liver Disease
09/25
09/25
NCT07030868: A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

Not yet recruiting
2
150
US, RoW
LY6249492, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
09/26
11/26
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
284
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
01/26
04/27
NCT05864391: A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

Terminated
1
40
US
AZD7503
AstraZeneca
Steatohepatitis
03/24
03/24
Gann, Crystal
NCT04783181: A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)

Active, not recruiting
1/2
8
US
AAV BBP-631
Adrenas Therapeutics Inc
Congenital Adrenal Hyperplasia
02/29
02/29

Download Options